Last Price
11.81
Today's Change
-0.14 (1.17%)
Day's Change
11.81 - 11.83
Trading Volume
1,692
Market Cap
498 Million
Shares Outstanding
41 Million
Avg Volume
16,408
Avg Price (50 Days)
11.69
Avg Price (200 Days)
11.68
PE Ratio
-7.24
EPS
-1.65
Earnings Announcement
08-Nov-2024
Previous Close
11.99
Open
11.95
Day's Range
11.94 - 11.975
Year Range
9.05 - 14.465
Trading Volume
8,837
1 Day Change
-0.33%
5 Day Change
-0.42%
1 Month Change
3.46%
3 Month Change
0.84%
6 Month Change
1.44%
Ytd Change
8.14%
1 Year Change
-9.13%
3 Year Change
23.58%
5 Year Change
23.20%
10 Year Change
23.20%
Max Change
23.20%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.